Biogen (BIIB) Spikes 14% After FDA Posts Briefing Documents for Alzheimer's Drug Aducanumab

(Updated - November 4, 2020 10:15 AM EST)

Biogen (NASDAQ: BIIB) shares spiked 14% and were halted due to volatility after FDA briefing documents for a review of Alzheimer's drug Aducanumab were posted.

Aducanumab was found to be effective enough to support approval, the FDA panel said in the documents.

You May Also Be Interested In

• Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
• Verastem reports early trial data for KRAS G12D cancer drug VS-7375
• NeOnc gets UAE approval for NEO100 brain cancer drug trials